Annovis Bio, Inc. (ANVS)

USD 4.71

(-7.83%)

Total Debt Summary of Annovis Bio, Inc.

  • Annovis Bio, Inc.'s latest annual total debt in 2023 was - USD , down 0.0% from previous year.
  • Annovis Bio, Inc.'s latest quarterly total debt in 2024 Q2 was - USD , down 0.0% from previous quarter.
  • Annovis Bio, Inc. reported annual total debt of - USD in 2022, down 0.0% from previous year.
  • Annovis Bio, Inc. reported annual total debt of - USD in 2021, down 0.0% from previous year.
  • Annovis Bio, Inc. reported quarterly total debt of - USD for 2024 Q1, down 0.0% from previous quarter.
  • Annovis Bio, Inc. reported quarterly total debt of - USD for 2023 Q4, down 0.0% from previous quarter.

Annual Total Debt Chart of Annovis Bio, Inc. (2023 - 2017)

Historical Annual Total Debt of Annovis Bio, Inc. (2023 - 2017)

Year Total Debt Total Debt Growth
2023 - USD 0.0%
2022 - USD 0.0%
2021 - USD 0.0%
2020 - USD -100.0%
2019 499.8 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%

Peer Total Debt Comparison of Annovis Bio, Inc.

Name Total Debt Total Debt Difference
ADC Therapeutics SA 124.37 Million USD 100.0%
Alto Neuroscience, Inc. 151.46 Million USD 100.0%
Biohaven Pharmaceutical Holding Company Ltd. 30.87 Million USD 100.0%
Ginkgo Bioworks Holdings, Inc. 241.76 Million USD 100.0%
Nuvation Bio Inc. 4 Million USD 100.0%
Nuvation Bio Inc. 4 Million USD 100.0%
Arcus Biosciences, Inc. 11 Million USD 100.0%
Theriva Biologics, Inc. 2.15 Million USD 100.0%
Zymeworks Inc. 26.72 Million USD 100.0%